(Reuters) - ZURICH, April 17 - Swiss drugmaker Novartis said on Tuesday it had received the approval in the United States for its Reclast drug as a treatment for Paget's disease of the bone.
"Reclast has received U.S. regulatory approval as the first new treatment in nearly a decade for patients with a bone condition known as Paget's disease, estimated to affect about one million people in the United States alone," Novartis said.
Read more at Reuters.com Government Filings News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment